None
Quote | G1 Therapeutics Inc. (NASDAQ:GTHX)
Last: | $4.32 |
---|---|
Change Percent: | 1.65% |
Open: | $4.2 |
Close: | $4.25 |
High: | $4.36 |
Low: | $4.13 |
Volume: | 490,766 |
Last Trade Date Time: | 05/08/2024 03:00:00 am |
News | G1 Therapeutics Inc. (NASDAQ:GTHX)
2024-05-01 12:04:08 ET G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Conference Call May 01, 2024 08:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chie...
2024-05-01 08:30:54 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook G1 Thera...
Message Board Posts | G1 Therapeutics Inc. (NASDAQ:GTHX)
Subject | By | Source | When |
---|---|---|---|
Thinking through this more- arent most CRC tumors | sks144 | investorshub | 02/28/2023 1:44:07 AM |
Agreed! Lets see how much cash they have | stocksrising | investorshub | 02/16/2023 1:42:45 AM |
I hope they survive. Drug has real potential | sks144 | investorshub | 02/15/2023 5:59:20 PM |
Lets see how much cash they have after | stocksrising | investorshub | 02/13/2023 7:36:32 PM |
What? Oh my!!! lolzzzzzzz | SurgeGuy2.0 | investorshub | 11/01/2021 9:44:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Pepper Bio, the world’s first transomics drug discovery and development company, announced a global licensing agreement (excluding t...